Expanding our US operations
We are delighted to announce that we have expanded our US operations, establishing offices in Boston, Los Angeles and San Francisco.
This is part of a major initiative to extend the company’s regional capacity within the US market. Research Partnership has appointed healthcare market research professionals Christine Naegle and Birgit Eschmann to run the company’s West Coast operations.
Fulham Green's Spring Breakfast BBQ
Spring is finally here, and what better way to celebrate the sun’s rays than on the grounds of Fulham Green, the location of our UK headquarters.
A big thank you to Fulham Green who organised the Spring Breakfast BBQ event where we were joined by some special guests; lambs, chicks, geese and a sheepdog! They have kindly put together a video as a memento of the day.
Removing the Roadblocks to Effective Patient Treatment
Mary Assimakopoulos, eyeforpharma April 12th 2013
Traditionally, pharma marketing has focused on understanding the needs and behaviour of physicians as the prescribers and decision-makers of medical brands. But there is an increasingly popular view which says that, in order to really influence prescribing decisions and improve outcomes, we need to understand more about the patient and the relationship they have with their physicians. The survey Living with rheumatoid arthritis (RA)*, recently carried out in the US and EU, amongst over 2,000 patients with moderate to severe RA, highlights this argument. During our research we identified four distinct patient types who are at different junctions along the RA journey. The largest segment, “Suffering Sarah”, offers the greatest opportunities for pharma to engage on an emotional level. Suffering Sarah represents 37% of the US and EU market, has the most severe / uncontrolled disease (which she feels has worsened since diagnosis) and is not receiving satisfactory treatment for her condition, despite being diagnosed for longer than other patient types. In our research we identified pivotal junctions in the patient journey, which represent opportunities for pharma to connect with the patient and set them on a positive path. If patients’ needs are not met at these stages, they can…